Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults: a randomized, double-blinded, immunobridging trial-Reference-Cited by-全球学者库

Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults: a randomized, double-blinded, immunobridging trial

Published:2023-07-11 Issue:1 Volume:22 Page:662-670
ISSN:1476-0584
Container-title:Expert Review of Vaccines
language:en
Short-container-title:Expert Review of Vaccines

Author:

Wu Yan-Fei¹,Wei Ming-Wei²,Wang Rui-Jie³,Guo Xi-Ling²,Pan Hong-Xing²,Gao Ya-Chun⁴,Li Xiao-Long³,Wang Xue³,Ma Xiao-Min³,Wan Peng⁵,Zhou Li⁵,Zhu Ya-Wen⁶,Li Jing-Xin¹²⁵⁶,Zhu Feng-Cai¹²⁵⁶

Affiliation:

1. School of Public Health, Southeast University, Nanjing, Jiangsu Province, China

2. NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, Jiangsu Province, China

3. Clinical operation center, CanSino Biologics Inc, Tianjin, P. R. China

4. Funing Country Center for Disease Control and Prevention, Yancheng, Jiangsu Province, China

5. Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu Province, China

6. Institute of Global Public Health and Emergency Pharmacy, China Pharmaceutical University, Nanjing, China

Funder

National Natural Science Foundation of China

Jiangsu Provincial Science Fund for Distinguished Young Scholars

Jiangsu Provincial Key Research and Development Program

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Molecular Medicine,Immunology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14760584.2023.2234997

Reference23 articles.

1. A Novel Coronavirus from Patients with Pneumonia in China, 2019

2. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia

3. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study

4. WHO. Coronavirus disease (COVID-19): Vaccines 2022 [cited 2022 Nov 21]. Available from: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-vaccines

5. WHO. Interim recommendations for use of the Cansino Ad5-nCoV-S vaccine (Convidecia ®) against COVID-19 19 May 2022; [cited 2022 Nov 24]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-Ad5-nCoV-Convidecia